Equipoise lost: Ethics, costs, and the regulation of cancer clinical research

Journal of Clinical Oncology

Volumn 28, Issue 17, 2010, Pages 2925-2935

  Stewart, David J ^a   Whitney, Simon N ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG MARKETING; EQUIPOISE; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; ARTICLE; CLINICAL TRIAL; ECONOMICS; ETHICS; FEMALE; LEGAL ASPECT; MALE; MEDICAL RESEARCH; NEOPLASM; RESEARCH ETHICS; STANDARD; TREATMENT OUTCOME; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; ETHICS, RESEARCH; FEMALE; HUMANS; MALE; NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 77956401725     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.5404     Document Type: Review

References (74)

1. The Heritage Illustrated Dictionary of the English Language, International Edition. New York, NY, American Heritage Publishing, 1973
2. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 317:141-145, 1987
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
4. Thornton M: The next front in the war on cancer. Wall Street Journal February 27, 2009:A17
5. Lowenstein PR, Lowenstein ED, Castro MG: Challenges in the evaluation, consent, ethics and history of early clinical trials: Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. Curr Opin Mol Ther 11:481-484, 2009
6. McCarthy M: US Food and Drug Administration pushed to change. Lancet 367:1643-1644, 2006
7. Rehnquist J: FDA's Review Process for New Drug Applications: A Management Review. Washington, DC, Department of Health and Human Services Office of Inspector General, 2003
8. Safeguarding clinical trials. Nat Med 13:107, 2007
9. Stewart PM, Stears A, Tomlinson JW, et al: Regulation: The real threat to clinical research. BMJ 337:a1732, 2008
10. Stewart DJ, Kurzrock R: Cancer: The road to Amiens. J Clin Oncol 27:328-333, 2009
11. Cheng SK, Dietrich MS, Finnigan S, et al: A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. J Clin Oncol 27:325s, 2009 (abstr CRA6509)
12. Durivage HJ, Bridges KD: Clinical trial metrics: Protocol performance and resource utilization from 14 cancer centers. J Clin Oncol 27:337s, 2009 (abstr 6557)
13. Wikipedia, the free encyclopedia: Health care in the United States. http://en.wikipedia.org/w/index.php?title=Health-care-in-the-United- States&oldid=294286977
14. Wikipedia, the free encyclopedia: List of countries by life expectancy. http://en.wikipedia.org/w/index.php?title=List-of-countries-by-life- expectancy&oldid=295218745
15. Wikipedia, the free encyclopedia: Autobahn. http://en.wikipedia.org/w/ index.php?title=Autobahn&oldid=294928914
16. Drug approval trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response. Business Insights, April 1, 2008
17. Freireich EJ: The investigational new drug application: Who benefits? Nat Clin Pract Oncol 3:62-63, 2006
18. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185, 2003 (Pubitemid 36279392)
19. Eichler HG, Abadie E, Raine JM, et al: Safe drugs and the cost of good intentions. N Engl J Med 360:1378-1380, 2009
20. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
21. Decoster G, Stein G, Holdener EE: Responses and toxic deaths in phase I clinical trials. Ann Oncol 1:175-181, 1990 (Pubitemid 20218532)
22. Lichter AL, Schnipper L, Emanual E: Presidential symposium: Report of the Clinical Trials Subcommittee. http://www.conference-cast.com/asco.org
23. Roche K, Paul N, Smuck B, et al: Factors affecting workload of cancer clinical trials: Results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 20:545-556, 2002 (Pubitemid 34081107)
24. Craft BS, Kurzrock R, Lei X, et al: The changing face of phase 1 cancer clinical trials: New challenges in study requirements. Cancer 115:1592-1597, 2009
25. Life Sciences World: Phase 3 clinical trial costs exceed $26,000 per patient, 2006. http://www.lifesciencesworld.com/news/view/11080
26. Couzin J: Stronger research just one item on drug agency's wish list. Science 323:1549, 2009
27. Berry SR, Neumann PJ, Bell C, et al: What price for a year of life? A survey of US and Canadian oncologists. J Clin Oncol 27:339s, 2009 (abstr 6565)
28. Cohen BL: Society's valuation of life saving in radiation protection and other contexts. Health Phys 38:33-51, 1980
29. Winkelmayer WC, Weinstein MC, Mittleman MA, et al: Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 22:417-430, 2002
30. Franco OH, Peeters A, Looman CW, et al: Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health 59:927-933, 2005 (Pubitemid 41527417)
31. Liberato NL, Marchetti M, Barosi G: Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25:625-633, 2007 (Pubitemid 350002916)
32. Sonnenberg A, Delco F, Inadomi JM: Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 133:573-584, 2000
33. Grusenmeyer P, Gralla R: Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non-small cell lung cancer. J Clin Oncol 24:314s 2006 (abstr 6057)
34. Young M, Plosker G: Paclitaxel: A pharmacoeconomic review of its use in ovarian cancer. Pharmacoeconomics 19:1227-1259, 2001 (Pubitemid 34074786)
35. Halfill T: Tom's inflation calculator. 2009. http://www.halfhill.com/ inflation.html
36. Masia N: The cost of developing a new drug. In: Clack G, Neely MS (eds): Focus on Intellectual Property Rights. Washington, DC, US Department of State Bureau of International Information Programs, 2008, pp 82-83
37. Dickson M, Gagnon JP: The cost of new drug discovery and development. Discov Med 4:172-179, 2004
38. DiMasi JA, Grabowski HG: Economics of new oncology drug development. J Clin Oncol 25:209-216, 2007 (Pubitemid 350003036)
39. Dilts DM, Sandler AB, Baker M, et al: Processes to activate phase III clinical trials in a Cooperative Oncology Group: The case of Cancer and Leukemia Group B. J Clin Oncol 24:4553-4557, 2006 (Pubitemid 46630950)
40. Dilts DM, Sandler A, Cheng S, et al: Development of clinical trials in a cooperative group setting: The Eastern Cooperative Oncology Group. Clin Cancer Res 14:3427-3433, 2008
41. Dilts DM, Sandler AB, Cheng SK, et al: Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol 27:1761-1766, 2009
42. Dilts DM, Sandler AB: Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 24:4545-4552, 2006 (Pubitemid 46630949)
43. Milne CP: Orphan products: Pain relief for clinical development headaches. Nat Biotechnol 20: 780-784, 2002
44. Sateren WB, Trimble EL, Abrams J, et al: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109-2117, 2002 (Pubitemid 34408802)
45. Vickers AJ: Do we want more cancer patients on clinical trials? If so, what are the barriers to greater accrual? Trials 9:31, 2008
46. Schechter AN: The crisis in clinical research: Endangering the half-century National Institutes of Health Consensus. JAMA 280:1440-1442, 1998
47. Christie DR, Gabriel GS, Dear K: Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: How many patients die waiting? Intern Med J 37:680-686, 2007
48. Reichert J: Clinical development of therapeutic medicines: A biopharmaceutical versus pharmaceutical product comparison. Drug Information J 35:337-346, 2001
49. Lopes Pegna A, Picozzi G: Lung cancer screening update. Curr Opin Pulm Med 15:327-333, 2009
50. Vioxx MDL Plaintiffs' Steering Committee: Vioxx Settlement. http://www.officialvioxxsettlement.com
51. Bardach E, Kagan RA: Going by the Book: The Problem of Regulatory Unreasonableness (ed 2). New Brunswick, NJ, Transaction Books, 2002
52. Rand A: Atlas Shrugged. New York, NY, Random House, 1957
53. Slevin ML, Stubbs L, Plant HJ, et al: Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300:1458-1460, 1990 (Pubitemid 20195333)
54. Seidenfeld J, Horstmann E, Emanuel EJ, et al: Participants in phase 1 oncology research trials: Are they vulnerable? Arch Intern Med 168:16-20, 2008
55. Goss E, Link MP, Bruinooge SS, et al: The impact of the privacy rule on cancer research: Variations in attitudes and application of regulatory standards. J Clin Oncol 27:4014-4020, 2009
56. Newell DR, Burtles SS, Fox BW, et al: Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer 81:760-768, 1999 (Pubitemid 29504682)
57. Newell DR, Silvester J, McDowell C, et al: The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. Eur J Cancer 40:899-906, 2004 (Pubitemid 38519768)
58. Humphreys K, Trafton J, Wagner TH: The cost of institutional review board procedures in multicenter observational research. Ann Intern Med 139: 77, 2003 (Pubitemid 38124625)
59. Byrne MM, Speckman J, Getz K, et al: Variability in the costs of institutional review board oversight. Acad Med 81:708-712, 2006 (Pubitemid 44167309)
60. Sugarman J, Getz K, Speckman JL, et al: The cost of institutional review boards in academic medical centers. N Engl J Med 352:1825-1827, 2005
61. Sobolski GK, Flores L, Emanuel EJ: Institutional review board review of multicenter studies. Ann Intern Med 146:759, 2007 (Pubitemid 351640009)
62. Emanuel EJ, Wood A, Fleischman A, et al: Oversight of human participants research: Identifying problems to evaluate reform proposals. Ann Intern Med 141:282-291, 2004 (Pubitemid 39089129)
63. George SL: Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 14:1364-1370, 1996
64. Horning SJ: Cancer research and privacy: The problem with being joined at the hip. J Clin Oncol 27:3879-3880, 2009
65. Braiteh F, Kurzrock R: Uncommon tumors and exceptional therapies: Paradox or paradigm? Mol Cancer Ther 6:1175-1179, 2007
66. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005 (Pubitemid 41540110)
67. Shepherd FA, Rodrigues Pereira J, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
68. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002 (Pubitemid 35334760)
69. El-Maraghi RH, Eisenhauer EA: Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J Clin Oncol 26:1346-1354, 2008
70. Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52:261-288, 1998 (Pubitemid 29056100)
71. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
72. Tsimberidou A, Braiteh F, Stewart DJ, et al: Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial. J Clin Oncol 27:6243-6250, 2009
73. Mok TS, Wu YL, Thongprasert S, et al; Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-57, 2009
74. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008